Expert Opinion on Drug Metabolism & Toxicology

Expert Opinion on Drug Metabolism & Toxicology

EXPERT OPIN DRUG MET
影响因子:3.4
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:ENGLAND
出版社:Taylor and Francis Ltd.
发刊时间:2005
发刊频率:Bimonthly
收录数据库:SCIE/Scopus收录
ISSN:1742-5255

期刊介绍

Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome:Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data.Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug.The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.
药物代谢和毒理学专家意见(ISSN 1742-5255 [印刷版],1744-7607 [电子版])是一份MEDLINE索引、同行评审的国际期刊,发表了关于ADME-Tox所有方面的综述文章。每篇文章的结构都包含了作者对未来发展范围的专家意见。编辑们欢迎:综述涉及与特定药物、药物相互作用、药物类别或其在特定人群中的使用相关的代谢、药代动力学和毒理学问题;与涉及药物代谢、处置和排泄的酶有关的问题;涉及药物代谢和毒理学研究的技术;获取ADME-Tox数据的新技术。药物评估回顾特定药物的临床、毒理学和药代动力学数据。受众包括制药行业的科学家和管理人员、药理学家、临床毒理学家和相关专业人士。
年发文量 100
国人发稿量 14.1
国人发文占比 0.14%
自引率 -
平均录取率0
平均审稿周期 偏慢,4-8周
版面费 -
偏重研究方向 医学-生化与分子生物学
期刊官网 http://www.tandfonline.com/loi/iemt20#.V48aFkz9cSQ
投稿链接 https://mc.manuscriptcentral.com/eomt

期刊高被引文献

Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1574744
Chemical activation of estrogen and aryl hydrocarbon receptor signaling pathways and their interaction in toxicology and metabolism
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1569627
Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1604685
Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1621289
Pharmacokinetics and pharmacodynamics of new acute treatments for migraine
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1578749
Pharmacogenetics of treatments for pancreatic cancer
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1620731
Pharmacogenetics of alcohol use disorder treatments: an update
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1628218
Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1600670
What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1631285
Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1588884
Venetoclax in the treatment of chronic lymphocytic leukemia
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1606211
Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1622679
Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1637417
Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1634053
Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1689958
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1663169
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1607292
Pharmacokinetic mechanisms underlying the detoxification effect of Glycyrrhizae Radix et Rhizoma (Gancao): drug metabolizing enzymes, transporters, and beyond
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1563595
Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1621838
Key insights from therapeutic drug monitoring in Crohn’s disease patients
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1597054
Drug-drug interactions between antiepileptics and cannabinoids
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1605355
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1700951
Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1700950
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1681969
Drug–drug interactions in patients receiving hematopoietic stem cell transplantation
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1552256
Monoclonal antibodies in severe asthma: is it worth it?
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1621837
Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1560420
Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1577821
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1675636
Clinically relevant drug interactions between newer antidepressants and oral anticoagulants
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2020.1700952
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1559816
An update on polyphenol disposition via coupled metabolic pathways
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1559815
Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1642323
Enhancement of lung levels of antibiotics by ambroxol and bromhexine
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1578748
Modulation of expression/function of intestinal P-glycoprotein under disease states
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2020.1701653
Is cytochrome oxidase inhibition the primary mechanism in aluminum phosphide poisoning?
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1645833
Pharmacokinetic considerations for current state-of-the-art antidepressants
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1669560
Factors influencing hepatic metabolism of antihypertensive drugs: impact on clinical response
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1558204
Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1623878
Perspectives on adjunctive use of ketamine for analgosedation during extracorporeal membrane oxygenation
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1593963
Tacrolimus in adult hematopoietic stem cell transplantation
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1675635
Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1681399
The transition of lead and microbial contamination from adulterated opium to the human body
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1588250
In vitro–in vivo correlation of the drug–drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1681968
Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1658742
Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1678584
Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1678585
Mitochondrial dysfunctions in HIV infection and antiviral drug treatment
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1692814
The effects of fasting on drug metabolism
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2020.1706728
Sunscreen ingredients in plasma: a threat for drug–drug interactions and toxicity among patients living with HIV?
来源期刊:Expert Opinion on Drug Metabolism & ToxicologyDOI:10.1080/17425255.2019.1670164

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
1.00%14.11%-0.99%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q2区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
BIOCHEMISTRY & MOLECULAR BIOLOGY
Q2

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学3区
TOXICOLOGY 毒理学
2区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
3区
PHARMACOLOGY & PHARMACY 药学
3区
2023年12月升级版
医学3区
PHARMACOLOGY & PHARMACY 药学
2区
TOXICOLOGY 毒理学
2区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
3区
2022年12月旧的升级版
医学2区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学
2区
PHARMACOLOGY & PHARMACY 药学
2区
TOXICOLOGY 毒理学
2区